Physicians 2 Pharma Workshop

Only Medics will be hosting a day of workshops for medics looking to transition to the pharmaceutical industry. The workshop will take place on Thursday 26th September in Reading, UK.  Attendance to the workshop is by invitation only. In addition to medics, the workshop will be attended by industry physicians and HR professionals, some of whom are actively

Continue Reading

AstraZeneca Acquires AlphaCore Pharma

AstraZeneca have today announced that they are expanding their cardiovascular and metabolic disease pipeline with the acquisition of AlphaCore Pharma. AlphaCore are a Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. AstraZeneca’s MedImmune unit is buying privately-held AlphaCore primarily because of ACP-501.  AstraZeneca note that LCAT is

Continue Reading

Agennix Cuts 55% of Jobs

After the failure of their experimental lung cancer drug, talactoferrin, in a late-stage clinical trial, Germany’s Agennix announced on Friday that they are reducing their workforce by roughly 55%. The restructuring plan will result in 37 jobs being lost and the firm’s Houston, USA site being closed down.  Around 30 staff will remain in the

Continue Reading

Competition Warning for Eight NHS Trusts

Eight NHS hospital trusts have provided guarantees to the Office of Fair Trading (OFT) that they will stop exchanging commercially-sensitive information about their Private Patient Unit (PPU) prices, and ensure that they conform to competition law. The Office of Fair Trading confronted members of the Southern Region Private Healthcare Association (SPHA) earlier this year, after

Continue Reading

AstraZeneca Teams With Regulus’ MicroRNA Therapeutics

AstraZeneca has announced that they have entered into a strategic partnership with US biopharmaceutical group Regulus Therapeutics to discover, develop, and commercialise microRNA therapeutics. The Anglo-Swedish drug giant has agreed to pay $28 million, which includes an equity investment and an upfront fee, so they can exclusively work with Regulus on the development of three

Continue Reading

Elan Separates Discovery Activities into Neotope

Elan today has announced that they have decided to spin off of their discovery science and Neotope Biosciences divisions into a separate business entity “to create two independent, highly focused, public companies.” After the separation, Elan will hold three key assets: the multiple sclerosis blockbuster Tysabri and its other potential indications; ELND005, a Phase II/Phase

Continue Reading